Obstetric and Gynecologic Imaging

Which Follow-up Imaging Is Best for an Indeterminate Adnexal Mass in Premenopausal Women?

·
Which Follow-up Imaging Is Best for an Indeterminate Adnexal Mass in Premenopausal Women?

A 34-year-old premenopausal woman is in your clinic for follow-up of an adnexal mass found incidentally on a pelvic ultrasound six weeks ago. The initial report described a 4 cm complex cystic structure, concluding it was “indeterminate.” The patient is asymptomatic and her physical exam is unremarkable. You now face the decision of how to further evaluate this finding to distinguish a transient physiologic cyst from a persistent, potentially neoplastic lesion. This article details the evidence-based clinical workflow for selecting the next imaging study in this specific scenario. According to the American College of Radiology (ACR) Appropriateness Criteria, a follow-up `US duplex Doppler pelvis` is rated Usually Appropriate as the next step.

Who Fits This Clinical Scenario for an Indeterminate Adnexal Mass?

This guidance applies to a specific patient population: a premenopausal adult female with a previously identified adnexal mass that was characterized as indeterminate on an initial pelvic ultrasound. The key elements defining this scenario are:

  • Premenopausal Status: The patient is of reproductive age with regular or irregular menstrual cycles. This hormonal status significantly influences the differential diagnosis, as physiologic and hemorrhagic cysts are common.
  • Indeterminate Initial Ultrasound: The first ultrasound revealed features that were neither definitively benign (e.g., a simple cyst) nor clearly malignant. These features might include thick septations, a solid-appearing component, or internal echoes of unclear etiology.
  • No Acute Symptoms: The patient does not present with acute pelvic pain, fever, signs of peritonitis, or hemodynamic instability. The presence of acute symptoms would suggest potential adnexal torsion, hemorrhage, or rupture, which requires an entirely different and more urgent diagnostic pathway.
  • Follow-up Imaging: This workflow is for the second or subsequent imaging study, not the initial evaluation of a palpable mass or suspected adnexal lesion.

This guidance should not be applied to patients who fall into different clinical categories, such as postmenopausal women, where the pre-test probability of malignancy is higher. Similarly, if the initial ultrasound confidently characterized the mass as “likely benign,” a less intensive follow-up protocol is warranted. Patients presenting with acute symptoms or those with a mass highly suspicious for malignancy on the initial ultrasound also follow separate, more aggressive management algorithms.

What Diagnoses Are You Working Up in This Scenario?

When an adnexal mass in a premenopausal woman is deemed indeterminate, the primary goal of follow-up imaging is to differentiate between transient, benign findings and persistent lesions that require further management or intervention. The differential diagnosis is broad, and the imaging aims to narrow these possibilities.

Hemorrhagic Ovarian Cyst: This is a very common cause of a complex-appearing mass in premenopausal women. Bleeding into a functional cyst creates internal echoes, septations, and a reticular “fishnet” pattern that can mimic a solid neoplasm on a single ultrasound. Follow-up imaging is crucial, as these cysts typically resolve or significantly decrease in size and complexity over one or two menstrual cycles.

Endometrioma: Also known as a “chocolate cyst,” an endometrioma is a collection of old blood from ectopic endometrial tissue within the ovary. While they often have a classic “ground-glass” appearance on ultrasound, they can also present with atypical features like solid-appearing nodules or fluid-fluid levels, making them indeterminate. They are typically persistent on follow-up imaging.

Mature Cystic Teratoma (Dermoid Cyst): These are common benign germ cell tumors. Their appearance on ultrasound can be highly variable due to the mix of tissues they contain, including fat, hair, and calcifications (teeth). This heterogeneity can lead to an indeterminate initial classification. Follow-up imaging helps confirm characteristic features, such as a Rokitansky nodule or fat-fluid levels.

Ovarian Neoplasm (Benign, Borderline, or Malignant): This is the most consequential consideration. The indeterminate features on the initial ultrasound—such as papillary projections, thick septations, or solid components with blood flow—may represent a true neoplasm. Follow-up imaging aims to better characterize these features using standardized systems like the Ovarian-Adnexal Reporting and Data System (O-RADS) to stratify the risk of malignancy and guide further management, which may include surgical consultation.

Why Is Follow-up Ultrasound the Recommended Study for This Presentation?

For a premenopausal woman with an asymptomatic, indeterminate adnexal mass, the ACR panel rates `US duplex Doppler pelvis`, `US pelvis transabdominal and US pelvis transvaginal`, and `US pelvis transvaginal` as Usually Appropriate. This strong recommendation for repeat ultrasound is based on its high diagnostic utility, safety profile, and ability to assess for change over time.

The primary rationale for a follow-up ultrasound is to determine if the mass is transient. Many indeterminate masses are functional or hemorrhagic cysts that will resolve or change significantly over 6 to 12 weeks. A repeat ultrasound can easily demonstrate this resolution, confirming a benign etiology and preventing unnecessary anxiety and further, more invasive workups.

Adding Duplex Doppler is key for characterizing persistent lesions. It assesses blood flow within the mass, a critical factor in risk stratification. The presence of vascularity within solid components or thick septations increases the suspicion for a neoplasm, whereas the absence of flow is reassuring. This functional information is a distinct advantage of ultrasound over non-contrast imaging modalities.

Critically, ultrasound involves no ionizing radiation (0 mSv), an essential consideration in a premenopausal patient who may require serial imaging over her lifetime.

Why Other Studies Are Rated Lower

  • MRI Pelvis without and with IV Contrast: While also rated Usually Appropriate, MRI is typically reserved as a problem-solving tool if the follow-up ultrasound remains indeterminate. It offers superior soft-tissue characterization and can be excellent for identifying fat in a dermoid cyst or confirming the nature of hemorrhagic products in an endometrioma. However, it is more costly and less accessible than ultrasound, making it a second-line choice for routine follow-up.
  • CT Pelvis with IV Contrast: This study is rated Usually not appropriate. CT provides inferior soft-tissue resolution of the adnexa compared to ultrasound and MRI. More importantly, it exposes a young, premenopausal patient to significant ionizing radiation (☢☢☢ 1-10 mSv) without offering a clear diagnostic advantage for this specific clinical question. Its use is generally reserved for staging known malignancies or in acute settings where other pathologies are suspected.

What’s Next After US duplex Doppler pelvis? Downstream Workflow

The results of the follow-up pelvic ultrasound will guide the next steps in a clear, branching pathway. The goal is to triage patients into three categories: confident benign finding, persistent indeterminate mass, or suspicious for malignancy.

  • If the Mass Has Resolved or Decreased in Size: If the follow-up ultrasound shows complete resolution or a significant decrease in the size and complexity of the mass, the finding is confirmed to be a transient hemorrhagic or functional cyst. No further imaging is typically required, and the patient can be reassured.
  • If the Mass Is Persistent but Appears Benign: If the mass persists but now displays classic benign features on the second look (e.g., a typical endometrioma or dermoid cyst), it can be managed according to established guidelines for those specific entities. This may involve continued surveillance or no further follow-up, depending on size and patient factors.
  • If the Mass Remains Indeterminate: If the follow-up ultrasound fails to clarify the nature of the mass, the next step is often problem-solving with a different modality. As per the ACR criteria, `MRI pelvis without and with IV contrast` is Usually Appropriate in this situation. MRI can provide superior tissue characterization to definitively identify the lesion or better stratify its risk.
  • If the Mass Is Suspicious for Malignancy: If the follow-up ultrasound reveals new or more prominent worrisome features—such as the development of solid nodules with Doppler flow, papillary projections, or an increase in size—the patient’s risk of malignancy is elevated. This finding should prompt an urgent referral to a gynecologic oncologist for surgical evaluation. Further cross-sectional imaging (CT or MRI) may be performed for preoperative planning but should not delay the specialist consultation.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup of an indeterminate adnexal mass requires careful attention to avoid common missteps that can lead to delayed diagnosis or unnecessary procedures.

  • Pitfall 1: Inappropriate Timing of Follow-up. Ordering a follow-up ultrasound too soon (e.g., within 1-2 weeks) may not allow enough time for a functional cyst to resolve, leading to a persistently indeterminate result. The ideal interval is typically 6-12 weeks, spanning at least one full menstrual cycle.
  • Pitfall 2: Prematurely Ordering CT. Reaching for a CT scan for initial characterization or routine follow-up is a frequent error. It exposes the patient to unnecessary radiation and provides less diagnostic information about ovarian pathology than a high-quality ultrasound or MRI.
  • Pitfall 3: Overlooking the Patient’s Age. The management and differential diagnosis for a premenopausal woman are fundamentally different from those for a postmenopausal woman. Applying postmenopausal risk algorithms (like a higher CA-125 cutoff) to a premenopausal patient can lead to inappropriate management.
  • Pitfall 4: Not Using a Standardized Reporting System. Encourage your radiology colleagues to use a system like O-RADS. This standardizes the description of findings and provides a clear risk score, which improves communication and guides management more effectively than a simple descriptive report.

If a mass persists after a follow-up ultrasound and remains indeterminate, or if it develops suspicious features, it is time to escalate care. This involves a referral to a gynecologist or, preferably, a gynecologic oncologist for further evaluation and management planning.

Related ACR Topics and Tools

This article covers one specific variant within a broader ACR topic. For a comprehensive overview of all related clinical scenarios, from initial imaging to postmenopausal follow-up, please consult the parent guide.

For additional decision support and technical guidance, the following GigHz tools are available:

Frequently Asked Questions

How long should I wait before ordering a follow-up ultrasound for an indeterminate adnexal mass?

The recommended interval is typically 6 to 12 weeks. This allows sufficient time for a transient functional or hemorrhagic cyst, a common cause of indeterminate findings, to resolve over one or two menstrual cycles. Imaging sooner may not show any change, leading to continued uncertainty.

Is an MRI a better first choice for follow-up than an ultrasound?

Not usually. While MRI is also rated ‘Usually Appropriate’ by the ACR, a follow-up ultrasound is the preferred initial step. It is more cost-effective, widely available, and excellent for determining if the mass is transient. MRI is best used as a problem-solving tool if the mass persists and remains indeterminate on the follow-up ultrasound.

Should I order a CA-125 blood test for a premenopausal woman with an indeterminate adnexal mass?

The utility of CA-125 is limited in premenopausal women because it can be elevated by many benign conditions, including endometriosis, fibroids, and even menstruation, leading to a high false-positive rate. It is generally not recommended as a routine screening tool in this population but may be considered by a specialist as part of a broader risk assessment for a persistent, suspicious mass.

What if the patient becomes symptomatic (e.g., develops severe pain) while awaiting follow-up imaging?

The development of acute symptoms like severe pain, fever, or dizziness is a red flag that changes the clinical scenario entirely. This could indicate adnexal torsion, hemorrhage, or rupture, and requires immediate evaluation in an emergency setting. The patient should be instructed to seek urgent medical care, where an immediate pelvic ultrasound would be performed.

Does the size of the indeterminate mass change the recommendation for follow-up ultrasound?

For most indeterminate masses in premenopausal women, the initial follow-up recommendation remains ultrasound regardless of size. However, very large masses (e.g., >7-10 cm) may prompt earlier consultation with a gynecologist, even while awaiting follow-up imaging, as size itself can be a risk factor for both torsion and malignancy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026